In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Christy Owings, Thermo Fisher, discusses how customs delays and import complexity risk clinical trial supply chains in Latin America. Christy Owings, Vice President and General Manager of the Americas ...
Vice President and General Manager, Clinical Trials, Americas, at Thermo Fisher Scientific. With more than 20 years of ...
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...
Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...
Continuous direct compression can provide a simplified alternative pathway for selected spray-dried dispersion formulations ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results